Ovation Pharmaceuticals is a biopharmaceutical company that specializes in developing, manufacturing, and selling innovative pharmaceutical products. Founded in 2000, the company has made significant strides in empowering patient care worldwide through its extensive global reach. In March 2009, Lundbeck, Inc. acquired Ovation Pharmaceuticals, and it now operates as a subsidiary of H. Lundbeck A/S.
Lundbeck, Inc. focuses on a wide range of pharmaceutical products addressing issues related to the central nervous system, hematology, and oncology. Some of its key products include methamphetamine hydrochloride tablets, mephobarbital tablets, pentobarbital sodium injections, ethotoin tablets, and clorazepate dipotassium and tetrabenazine tablets. Additionally, it offers a variety of other essential medications such as antithrombin, dactinomycin, asparaginase, mechlorethamine, and hemin injections, which are used in hospitals.
One of the key strengths of Ovation Pharmaceuticals is its extensive international presence, with its products being marketed in numerous countries across the globe. These include, but are not limited to, Argentina, Brazil, Canada, Costa Rica, Guatemala, Honduras, Mexico, Australia, Hong Kong, Korea, Malaysia, New Zealand, the Philippines, Singapore, Taiwan, Thailand, Austria, Belgium, Bulgaria, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, the United Kingdom, and Israel.
The acquisition by Lundbeck, Inc. has provided Ovation Pharmaceuticals with a strong foundation for further expansion and innovation in the biotechnology and manufacturing industries, positioning it as a key player in the global pharmaceutical market.
